Press Releases


Press Releases

Date Title and Summary
Toggle Summary Foamix Announces Appointment of Matt Wiley as Chief Commercial Officer
REHOVOT, Israel , and BRIDGEWATER, N.J. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the
Toggle Summary Foamix Announces Appointment of Anthony Bruno to Board of Directors
REHOVOT, Israel and BRIDGEWATER, N.J. , Nov. 19, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the
Toggle Summary Foamix Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Conference Call and Webcast Thursday, November 8, @ 8.30 am Eastern Time REHOVOT, Israel , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing
Toggle Summary Foamix Announces Positive Topline Results from Phase 3 Program Evaluating FMX103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea
FMX103 Demonstrated Highly Statistically Significant Improvement Compared with Vehicle in Both Co-Primary Efficacy Endpoints Conference Call and Webcast Today at 8:30 a.m. ET REHOVOT, Israel and BRIDGEWATER, N.J. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd.
Toggle Summary Foamix Pharmaceuticals Third Quarter Financial Results Conference Call & Webcast Scheduled for November 8
REHOVOT, Israel , and BRIDGEWATER, N.J. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today
Toggle Summary Foamix to Present Clinical Data From Study FX2017-22 at the Fall Clinical Dermatology Conference
REHOVOT, Israel and BRIDGEWATER, N.J. , Oct. 12, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today
Toggle Summary Foamix Announces Additional Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne
Statistically significant improvement demonstrated in reduction of non-inflammatory lesions Dermal tolerability scores consistent with previous Phase 3 studies Re-analysis including patients from discontinued investigator site consistent with primary ITT analysis for both co-primary endpoints,
Toggle Summary Foamix Pharmaceuticals to Participate in the Cantor Fitzgerald Global Healthcare Conference
REHOVOT, Israel and BRIDGEWATER, N.J. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary, topical therapies to address unmet needs in dermatology, announced today
Toggle Summary Foamix Announces Closing of its Follow-on Offering of Ordinary Shares and Full Exercise of its Option by the Underwriters
REHOVOT, Israel , and BRIDGEWATER, N.J. , Sept. 18, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (“Foamix”) (Nasdaq: FOMX), a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary, topical therapies to address unmet needs in dermatology, today
Toggle Summary Foamix Announces Pricing of its Follow-on Offering of Ordinary Shares
REHOVOT, Israel and BRIDGEWATER, N.J. , Sept. 13, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (“Foamix”) (Nasdaq: FOMX), a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary, topical therapies to address unmet needs in dermatology, today
Toggle Summary Foamix Announces Proposed Follow-on Offering of Ordinary Shares
REHOVOT, Israel , and BRIDGEWATER, N.J. , Sept. 12, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (“Foamix”) (Nasdaq: FOMX), a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today
Toggle Summary Foamix Announces Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne
FMX101 Demonstrated Highly Statistically Significant Improvement Compared with Vehicle in Both Co-Primary Efficacy Endpoints Conference Call and Webcast Tomorrow at 8:00 a.m. EDT REHOVOT, Israel and BRIDGEWATER, N.J. , Sept. 11, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd.
Toggle Summary Foamix Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Rehovot, Israel, August 8, 2018 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today its financial results for the second quarter and six months ended June 30, 2018.
Toggle Summary Foamix Pharmaceuticals to Announce Second Quarter Financial Results on August 8
Rehovot, Israel, and Bridgewater, NJ – August 1st, 2018 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will report financial results for the three and six-month periods ended June 30, 2018, on Wednesday, August 8 after the markets close.
Toggle Summary Foamix Announces Dosing of Last Patient in Phase 3 Rosacea Studies for Minocycline Foam FMX103
Top-line results expected early Q4 2018 Rehovot, Israel, and Bridgewater, NJ – June 27, 2018  – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology,
Toggle Summary Foamix Pharmaceuticals to Participate in the Cantor Dermatology & Aesthetics Summit
REHOVOT, Israel and BRIDGEWATER, N.J. , June 14, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that
Toggle Summary Foamix Reports First Quarter 2018 Financial Results and Provides Corporate Update
Conference Call and Webcast on Wednesday, May 9 at 8:30am Eastern Time REHOVOT, Israel , May 08, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary
Toggle Summary Foamix Announces Dosing of Last Patient in Third Phase 3 Acne Study for Minocycline Foam FMX101
Top-line Results Expected in the Third Quarter of 2018 REHOVOT, Israel , and BRIDGEWATER, N.J. , May 07, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to
Toggle Summary Foamix Pharmaceuticals First Quarter Financial Results Conference Call & Webcast Scheduled for May 9
REHOVOT, Israel , and BRIDGEWATER, N.J. , April 24, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Announces $16 Million Investment by OrbiMed
REHOVOT, Israel and BRIDGEWATER, N.J. , April 16, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today